ImmunoCellular Therapeutics, Ltd. (IMUC)
USD 0.15
(53.85%)
USD 0.15
(53.85%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.45 Million USD | 56.17% |
| 2022 | 2.85 Million USD | 2601.25% |
| 2021 | -114.1 Thousand USD | 56.61% |
| 2020 | -262.97 Thousand USD | 0.0% |
| 2017 | -6.62 Million USD | 42.03% |
| 2016 | -11.43 Million USD | 49.4% |
| 2015 | -22.6 Million USD | 2.66% |
| 2014 | -23.22 Million USD | 16.0% |
| 2013 | -27.64 Million USD | -5.45% |
| 2012 | -26.21 Million USD | -294.05% |
| 2011 | -6.65 Million USD | -25.06% |
| 2010 | -5.31 Million USD | -1505.47% |
| 2009 | -331.35 Thousand USD | -288.5% |
| 2008 | -85.29 Thousand USD | 98.31% |
| 2007 | -5.04 Million USD | -375.4% |
| 2006 | -1.06 Million USD | -3372.2% |
| 2005 | -30.53 Thousand USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 FY | 4.45 Million USD | 56.17% |
| 2022 FY | 2.85 Million USD | 2601.25% |
| 2022 Q4 | 2.85 Million USD | 14.25% |
| 2022 Q3 | 2.49 Million USD | 0.0% |
| 2022 Q1 | 1.84 Million USD | 38.51% |
| 2021 FY | -114.1 Thousand USD | 56.61% |
| 2021 Q3 | 1.18 Million USD | 0.0% |
| 2021 Q1 | 262.97 Thousand USD | 200.0% |
| 2021 Q4 | 1.33 Million USD | 11.86% |
| 2020 Q4 | -262.97 Thousand USD | 0.0% |
| 2020 FY | -262.97 Thousand USD | 0.0% |
| 2018 Q2 | -2.85 Million USD | 43.25% |
| 2018 Q1 | -5.02 Million USD | 24.18% |
| 2017 Q2 | -1.81 Million USD | 66.04% |
| 2017 Q4 | -6.62 Million USD | -10.4% |
| 2017 FY | -6.62 Million USD | 42.03% |
| 2017 Q3 | -6 Million USD | -231.05% |
| 2017 Q1 | -5.34 Million USD | 53.3% |
| 2016 Q4 | -11.43 Million USD | 25.24% |
| 2016 Q3 | -15.29 Million USD | -28.03% |
| 2016 Q1 | -17.51 Million USD | 22.52% |
| 2016 Q2 | -11.94 Million USD | 31.78% |
| 2016 FY | -11.43 Million USD | 49.4% |
| 2015 Q2 | -30.9 Million USD | 11.11% |
| 2015 FY | -22.6 Million USD | 2.66% |
| 2015 Q4 | -22.6 Million USD | 7.49% |
| 2015 Q1 | -34.77 Million USD | -49.73% |
| 2015 Q3 | -24.43 Million USD | 20.94% |
| 2014 Q4 | -23.22 Million USD | 1.25% |
| 2014 Q3 | -23.51 Million USD | 8.36% |
| 2014 Q2 | -25.66 Million USD | -2.52% |
| 2014 Q1 | -25.02 Million USD | 9.47% |
| 2014 FY | -23.22 Million USD | 16.0% |
| 2013 Q2 | -25.45 Million USD | -5.59% |
| 2013 FY | -27.64 Million USD | -5.45% |
| 2013 Q4 | -27.64 Million USD | 6.07% |
| 2013 Q3 | -29.43 Million USD | -15.64% |
| 2013 Q1 | -24.1 Million USD | 8.06% |
| 2012 Q3 | -10 Million USD | 11.77% |
| 2012 Q1 | -13.55 Million USD | -103.75% |
| 2012 Q2 | -11.33 Million USD | 16.35% |
| 2012 FY | -26.21 Million USD | -294.05% |
| 2012 Q4 | -26.21 Million USD | -162.02% |
| 2011 FY | -6.65 Million USD | -25.06% |
| 2011 Q1 | -11.25 Million USD | -111.55% |
| 2011 Q2 | -10.14 Million USD | 9.83% |
| 2011 Q3 | -8.55 Million USD | 15.73% |
| 2011 Q4 | -6.65 Million USD | 22.2% |
| 2010 Q1 | -2.41 Million USD | -628.88% |
| 2010 Q3 | -6.24 Million USD | 19.38% |
| 2010 Q2 | -7.74 Million USD | -220.73% |
| 2010 Q4 | -5.31 Million USD | 14.82% |
| 2010 FY | -5.31 Million USD | -1505.47% |
| 2009 Q1 | -2.55 Million USD | -2900.46% |
| 2009 Q3 | -1.66 Million USD | 25.71% |
| 2009 FY | -331.35 Thousand USD | -288.5% |
| 2009 Q4 | -331.35 Thousand USD | 80.16% |
| 2009 Q2 | -2.24 Million USD | 12.17% |
| 2008 Q2 | -3.96 Million USD | 10.91% |
| 2008 FY | -85.29 Thousand USD | 98.31% |
| 2008 Q4 | -85.29 Thousand USD | 97.57% |
| 2008 Q1 | -4.44 Million USD | 11.77% |
| 2008 Q3 | -3.5 Million USD | 11.43% |
| 2007 FY | -5.04 Million USD | -375.4% |
| 2007 Q4 | -5.04 Million USD | 6.05% |
| 2007 Q3 | -5.36 Million USD | 1.46% |
| 2007 Q1 | -1.9 Million USD | -79.75% |
| 2007 Q2 | -5.44 Million USD | -185.69% |
| 2006 Q2 | -1.18 Million USD | 8.88% |
| 2006 FY | -1.06 Million USD | -3372.2% |
| 2006 Q4 | -1.06 Million USD | 5.32% |
| 2006 Q3 | -1.11 Million USD | 5.75% |
| 2006 Q1 | -1.3 Million USD | 0.0% |
| 2005 FY | -30.53 Thousand USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 340330.687% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 21.092% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 89.585% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1885.523% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1361.319% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 170.696% |
| Qrons Inc. | 351.42 Thousand USD | -1168.264% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -616.144% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 89.738% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 21939.583% |
| Skye Bioscience, Inc. | -5.72 Million USD | 177.901% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 71.725% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -8.232% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1009.129% |
| SQZ Biotechnologies Company | -36.23 Million USD | 112.299% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -98.776% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -380.704% |
| Mesoblast Limited | 55.85 Million USD | 92.021% |
| Marizyme, Inc. | 18.56 Million USD | 75.998% |
| Genus plc | 190.6 Million USD | 97.662% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -99.345% |
| Pharming Group N.V. | 109.8 Million USD | 95.941% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -418.113% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -267.169% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -555.444% |
| ContraFect Corporation | -6.02 Million USD | 173.963% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -3210.35% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -285.746% |
| IMV Inc. | 7.67 Million USD | 41.894% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 18.991% |
| MultiCell Technologies, Inc. | 90.04 USD | -4949946.646% |
| ONE Bio Corp. | 9.04 Million USD | 50.697% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 707.242% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 65.572% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -225.813% |
| Q BioMed Inc. | 4.06 Million USD | -9.779% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 85.413% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -342.289% |
| Biomind Labs Inc. | 711.4 Thousand USD | -526.512% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 92.639% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -122.919% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 65.197% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1139.06% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -3088.05% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -22334.298% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -102.41% |
| GB Sciences, Inc. | 1.74 Million USD | -155.078% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 2525.089% |
| HST Global, Inc. | 96.79 Thousand USD | -4504.695% |
| CSL Limited | 10.52 Billion USD | 99.958% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -2061.326% |
| Halberd Corporation | 144.72 Thousand USD | -2979.734% |
| Enzolytics Inc. | 981.65 Thousand USD | -354.031% |
| Agentix Corp. | 37.63 Thousand USD | -11744.017% |
| Resverlogix Corp. | 6.45 Million USD | 30.91% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 762.174% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.22% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 109.481% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 36.967% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -64.55% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 150.419% |
| AVAX Technologies, Inc. | -5.9 Million USD | 175.502% |
| Zenith Capital Corp. | 10.06 Thousand USD | -44186.785% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.42% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -2123.708% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -86.796% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -2609.288% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 24431.379% |
| Kadimastem Ltd | -253.1 Thousand USD | 1860.959% |
| Helix BioMedix, Inc. | -2.57 Million USD | 273.423% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 78.018% |
| BioStem Technologies, Inc. | 4.47 Million USD | 0.335% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -2114.625% |
| LadRx Corporation | -2.03 Million USD | 318.86% |
| Cell Source, Inc. | 9.23 Million USD | 51.722% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -601.709% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -601.709% |
| NovAccess Global Inc. | 2.17 Million USD | -104.595% |
| Affymax, Inc. | -5.59 Million USD | 179.632% |
| Itoco Inc. | 228.3 Thousand USD | -1852.223% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -3177.487% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 10.086% |
| Mobile Lads Corp. | 484.23 Thousand USD | -820.431% |
| CytoDyn Inc. | 20.26 Million USD | 78.003% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 688975.116% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 48188.676% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 42.162% |
| SYBLEU INC | 473.71 Thousand USD | -840.868% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| International Stem Cell Corporation | 2.59 Million USD | -72.086% |
| Bioxytran, Inc. | 1.89 Million USD | -134.714% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -7041.176% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -104.366% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -29.791% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 47.889% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -476.881% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 456.562% |
| Neutra Corp. | 52.18 Thousand USD | -8440.483% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 279.069% |
| PureTech Health plc | -167.19 Million USD | 102.666% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1919.876% |
| IXICO plc | -4.44 Million USD | 200.28% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 66.283% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 91.874% |
| CSL Limited | 10.52 Billion USD | 99.958% |
| Cellectis S.A. | -43.81 Million USD | 110.171% |